Tanezumab, identified by the catalog designation 880266-57-9, represents a monoclonal antibody solution demonstrating significant potential in alleviating debilitating osteoarthritis pain. This modified antibody uniquely targets sensory growth element , reducing its activity and thereby diminishing pain within affected areas . The clinical data surrounding 880266-57-9 highlights its power to offer noticeable suffering alleviation while perhaps limiting the dependence for opioid analgesics. Further studies are currently underway to fully assess its lasting well-being and performance.
Understanding Tanezumab's Part in Pain Control: An Antibody Outlook
Tanezumab, a groundbreaking medicinal approach, offers a unique pathway in persistent pain management. As a monoclonal antibody, it specifically targets and prevents nerve expansion factor (NGF), a key molecule engaged in sensory discomfort signaling. Unlike traditional pain medications, tanezumab’s antibody mechanism allows for a greater precise action, possibly reducing the chance of some frequent side effects associated with systemic pain reduction. However, its protein nature necessitates a thorough assessment of anticipated body's responses and long-term effects when employed within a complete pain management program.
Tanezumab Solution (880266-57-9): Quality , Grade & Functions
The Tanezumab Compound with the identifier 880266-57-9 is a critical component in various research applications, particularly concerning chronic inflammation treatment development. Achieving a high standard of purity is paramount; therefore, rigorous testing protocols are employed to guarantee its appropriateness for specific use. Our production method focuses on ensuring cleanliness , employing sophisticated filtration techniques to remove impurities . Typical characteristics include a >95% purity grade as determined by Tanezumab antibody Liquid Chromatography and comprehensive examination for molecular integrity. The main uses revolve around its role as a scientific resource for investigating pathways of cartilage damage and developing novel therapeutic interventions .
- Scientific Investigations
- Therapeutic Development
- Process Studies
The Investigation Of Tanezumab:
Tanezumab, identified by the chemical identifier 880266-57-9, represents a innovative biological protein targeting nerve growth agent receptor (NGF). Its process of effect revolves upon specifically binding to NGF, as a result blocking its function and following communication transduction. Investigators have shown that this biologic agent presents potential for alleviating chronic suffering, particularly linked to illnesses like joint degeneration and lower back pain. More investigations are continuing to fully characterize its impact and well-being data.
Latest Developments in The Investigation: Examining the Its Reagent
Future analyses surrounding tanezumab, a promising therapeutic agent, are increasingly directed on understanding the role of the particular reagent, 880266-57-9. This discovery and detailed evaluation of this chemical entity seems crucial for enhancing tanezumab's performance and minimizing anticipated negative effects. Preliminary results suggest that 880266-57-9 plays a key role in the therapy's process of delivery. Further investigations remain essential to completely understand the reagent’s influence.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}